Distinct Patient, Tumour, Treatment Characteristics and a Different Pattern and Risk of Survival Events Over Time Between Young BRCA1/2 Carriers By Ogkologos - March 10, 2025 719 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a global cohort of patients harbouring germline pathogenic/likely pathogenic variants in BRCA1 or BRCA2 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR New Task Force Focuses on Quality of Life for AYAs with... August 4, 2021 4,000 Cancer Patients Affected by Diluted Chemotherapy Doses from Crooked Pharmacist September 17, 2020 Should CAR T Cells Be Used Earlier in People with Non-Hodgkin... January 13, 2022 Coming together for Zynlonta July 2, 2021 Load more HOT NEWS FDA Approves Entrectinib Based on Tumor Genetics Rather Than Cancer Type EMA Recommends Extension of Indications for Pembrolizumab to MSI-H or dMMR... Treating High-Risk Bladder Cancer and Analyzing PSA Screening for Prostate Cancer:... ESMO Congress 2021, 16-21 September